Scleroderma laboratory findings: Difference between revisions
| Line 26: | Line 26: | ||
*Laboratory findings consistent with the diagnosis of scleroderma include:<ref name="pmid6155920">{{cite journal |vauthors=Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C |title=Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome |journal=Arthritis Rheum. |volume=23 |issue=6 |pages=617–25 |date=June 1980 |pmid=6155920 |doi= |url=}}</ref> | *Laboratory findings consistent with the diagnosis of scleroderma include:<ref name="pmid6155920">{{cite journal |vauthors=Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C |title=Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome |journal=Arthritis Rheum. |volume=23 |issue=6 |pages=617–25 |date=June 1980 |pmid=6155920 |doi= |url=}}</ref> | ||
**Anti-Scl-70 antibody (Topoisomerase I) | **Anti-Scl-70 antibody (Topoisomerase I) | ||
**Anti-centromere antibody (CREST syndrome) | **Anti-centromere antibody (CREST syndrome)<ref name="pmid6384675">{{cite journal |vauthors=Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL |title=The anticentromere antibody: disease specificity and clinical significance |journal=Mayo Clin. Proc. |volume=59 |issue=10 |pages=700–6 |date=October 1984 |pmid=6384675 |doi= |url=}}</ref> | ||
**Anti-nuclear antibody (ANA) | **Anti-nuclear antibody (ANA) | ||
**Anti-RNA polymerase III antibody | **Anti-RNA polymerase III antibody | ||
Revision as of 16:20, 18 April 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Scleroderma laboratory findings |
|
Risk calculators and risk factors for Scleroderma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Laboratory findings consistent with the diagnosis of scleroderma include:[1]
- Anti-Scl-70 antibody (Topoisomerase I)
- Anti-centromere antibody (CREST syndrome)[2]
- Anti-nuclear antibody (ANA)
- Anti-RNA polymerase III antibody
- Anti-U1-RNP antibody
References
- ↑ Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (June 1980). "Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome". Arthritis Rheum. 23 (6): 617–25. PMID 6155920.
- ↑ Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (October 1984). "The anticentromere antibody: disease specificity and clinical significance". Mayo Clin. Proc. 59 (10): 700–6. PMID 6384675.